This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

BG Medicine, Inc. Announces Schedule Of Events Related To Galectin-3 At The 17th Annual Scientific Meeting Of The Heart Failure Society Of America

WALTHAM, Mass., Sept. 19, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a commercial stage company that is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders announced today a series of events related to galectin-3 and heart failure during the 17th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) taking place on September 22 nd-25 th, 2013 in Orlando, Florida.

On  Sunday, September 22 nd, immediately following the opening session , BG Medicine will co-sponsor an Early Career Professionals Reception with Boston Scientific Corporation. This event provides a rare opportunity for early career professionals to meet mentors and talk with some of the most respected heart failure specialists in America.

Galectin-3 will be featured in several oral presentations at the meeting including one entitled, "Novel Biomarkers for Heart Failure – Eventual Targets for Therapy" on Monday, September 23 rd at 4:00pm Eastern Time. Christopher deFilippi, MD, Associate Professor of Medicine at the University of Maryland will discuss Galectin-3 and the prognosis in heart failure during this presentation.

On  Tuesday, September 24 th, there will be a Galectin-3 presentation by Alan Maisel, MD, Professor of Medicine and Director of the Coronary Care Unit at the University of California San Diego and Michael Zile, MD, Principal Investigator at the Gazes Cardiac Research Institute and Professor of Medicine at Medical University in Charleston, South Carolina. The title of the program is "Development, progression and hospitalization for heart failure: targeting fibrosis" and will take place at 12:45pm Eastern Time in The Peabody Hotel Exhibit Hall.  This program will address the role of Galectin-3, a marker implicated in cardiac fibrosis, in the development of heart failure (HF) and how to use a biomarker guided approach to identify patients at high risk for near term hospitalization and mortality.

Abou t Galectin-3 Testing and Heart Failure

Galectin-3 has been implicated in a variety of biological processes important in the development and progression of heart failure. Higher levels of galectin-3 are associated with a more aggressive form of heart failure, which may make identification of high-risk patients using galectin-3 testing an important part of patient care. Galectin-3 testing may be useful in helping physicians determine which patients are at higher risk of death or hospitalization, including 30-day readmission. The BGM Galectin-3® blood test is to be used as an aid in assessing the prognosis of patients with chronic heart failure, in conjunction with clinical evaluation. For more information visit www.galectin-3.com

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD) is a commercial stage company that is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.BG-medicine.com . The BG Medicine Inc. logo is available for download here

CONTACT: BG-Medicine Investor Inquiries:
         Chuck Abdalian, EVP & Chief Financial Officer, (781) 434-0210

BG Medicine Inc. logo

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,265.99 +109.14 0.64%
S&P 500 2,011.36 +9.79 0.49%
NASDAQ 4,593.4250 +31.2360 0.68%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs